

# Hyperuricemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

## *Hyperuricemia Pipeline*

LAS VEGAS, NV, UNITED STATES, February 13, 2025 /EINPresswire.com/ -- DelveInsight's, "Hyperuricemia Pipeline Insight" report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Hyperuricemia pipeline landscape. It covers the Hyperuricemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hyperuricemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Hyperuricemia pipeline products in this space.



Hyperuricemia Pipeline

Stay ahead with the latest insights! Download DelveInsight's comprehensive Hyperuricemia Pipeline Report to explore emerging therapies, key Hyperuricemia Companies, and future Hyperuricemia treatment landscapes @ [Hyperuricemia Pipeline Outlook Report](#)

### Key Takeaways from the Hyperuricemia Pipeline Report

- In February 2025:- ArthroSi Therapeutics:- This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months.
- In January 2025:- Urica Therapeutics Inc.: A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of 7 days of treatment with two doses of dotinurad monotherapy, and to evaluate the effect of dotinurad, as monotherapy and in combination with allopurinol, versus allopurinol monotherapy, on the PK of each, and to assess the additive PD effects on serum uric acid and urinary urate excretion in U.S. patients with gout and hyperuricemia
- DelveInsight's Hyperuricemia pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Hyperuricemia treatment.
- The leading Hyperuricemia Companies such as Shanton Pharma, LG Chem, Sunshine Lake

Pharma, InventisBio, Jiangsu Atom Bioscience and Pharmaceutical, Nippon Chemiphar, and others.

- Promising Hyperuricemia Therapies such as D-0120, Benzbromaron, SHR4640, FYU-981, Topiroxostat, and others.

Discover how the Hyperuricemia treatment paradigm is evolving. Access DelveInsight's in-depth Hyperuricemia Pipeline Analysis for a closer look at promising breakthroughs @ [Hyperuricemia Clinical Trials and Studies](#)

#### Hyperuricemia Emerging Drugs

- ABP-671: Jiangsu Atom Bioscience

ABP-671, developed by Jiangsu Atom Bioscience and Pharmaceutical, is a small molecule under clinical development for treating gout associated with hyperuricemia. This drug is administered orally and acts by targeting the urate transporter 1 (URAT1) protein involved in uric acid reabsorption by the kidneys. ABP-671's mechanism of action involves inhibiting URAT1, which helps in reducing uric acid levels significantly and safely compared to existing gout treatments. This drug has shown promising results in clinical trials, demonstrating efficacy in maintaining serum uric acid levels within the recommended range for gout patients. Currently, the drug is in Phase III stage of its clinical trial for the treatment of hyperuricemia.

- LR19074: LG Life Sciences

LR19074 is a novel non-purine selective inhibitor of Xanthine Oxidase (XO). XO is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, this agent reduces uric acid concentrations in serum by inhibiting the production of uric acid by XO inhibition. LC350189 has the potential to address the unmet clinical needs for safety and efficacy in gout treatment. LC350189 showed good systemic exposures and sUA lowering effects with no significant safety concerns in Korean and the U.S. healthy volunteers. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Hyperuricemia.

- NC-2500: Nippon Chemiphar

NC-2500 is a novel advanced xanthine oxidoreductase (XOR) inhibitor, having potential to reduce the risk of gout flare, one of major issues of current treatments for gout, and make a difference in gout treatment. Currently, the drug is in Phase I stage of its clinical trial for the treatment of hyperuricemia.

The Hyperuricemia pipeline report provides insights into

- The report provides detailed insights about Hyperuricemia companies that are developing therapies for the treatment of Hyperuricemia with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hyperuricemia Treatment.
- Hyperuricemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

- Hyperuricemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hyperuricemia market.

Get a detailed analysis of the latest innovations in the Hyperuricemia pipeline. Explore DelveInsight's expert-driven report today! @ [Hyperuricemia Unmet Needs](#)

#### Hyperuricemia Companies

Shanton Pharma, LG Chem, Sunshine Lake Pharma, InventisBio, Jiangsu Atom Bioscience and Pharmaceutical, Nippon Chemiphar, and others.

Hyperuricemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical

Hyperuricemia Products have been categorized under various Molecule types such as

- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming Hyperuricemia Therapies and key Hyperuricemia Developments @ Hyperuricemia Market Drivers and Barriers, and Future Perspectives- [https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=ypr](https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr)

#### Scope of the Hyperuricemia Pipeline Report

- Coverage- Global
- Hyperuricemia Companies- Shanton Pharma, LG Chem, Sunshine Lake Pharma, InventisBio, Jiangsu Atom Bioscience and Pharmaceutical, Nippon Chemiphar, and others.
- Hyperuricemia Therapies- D-0120, Benzbromaron, SHR4640, FYU-981, Topiroxostat, and others.
- Hyperuricemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

- Hyperuricemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Hyperuricemia drug development? Find out in DelveInsight's exclusive Hyperuricemia Pipeline Report—access it now! @ Hyperuricemia Emerging Drugs and Major Companies- [https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=ypr](https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr)

## Table of Content

1. Introduction
2. Executive Summary
3. Hyperuricemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hyperuricemia – DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ABP-671: Jiansu Atom Bioscience
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. LR19074: LG Life Sciences
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. NC-2500: Nippon Chemiphar
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Hyperuricemia Key Companies
21. Hyperuricemia Key Products
22. Hyperuricemia - Unmet Needs
23. Hyperuricemia - Market Drivers and Barriers
24. Hyperuricemia - Future Perspectives and Conclusion
25. Hyperuricemia Analyst Views
26. Hyperuricemia Key Companies
27. Appendix

## List of Top Selling Market Research Reports in 2025

Athlete's Foot Market- <https://www.delveinsight.com/report-store/athletes-foot-market>

Tuberculosis Market- <https://www.delveinsight.com/report-store/tuberculosis-market>

Wound Healing Devices Market- <https://www.delveinsight.com/report-store/wound-healing->

[devices-market](#)

Attention Deficit Hyperactivity Disorder Market- <https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market>

Complex Regional Pain Syndrome Market- <https://www.delveinsight.com/report-store/complex-regional-pain-syndrome-crps-market>

Coronary Microvascular Dysfunction Market- <https://www.delveinsight.com/report-store/coronary-microvascular-dysfunction-market>

Diabetes Insipidus Market- <https://www.delveinsight.com/report-store/diabetes-insipidus-market>

HDAC Inhibitors Market- <https://www.delveinsight.com/report-store/hdac-inhibitor-pipeline-insight>

Healthcare Competitive Benchmarking- <https://www.delveinsight.com/consulting/competitive-benchmarking-services>

Heart Failure Market- <https://www.delveinsight.com/report-store/congestive-heart-failure-market>

Hyperphosphatemia Market- <https://www.delveinsight.com/report-store/hyperphosphatemia-market>

Immune Checkpoints Activators Market- <https://www.delveinsight.com/report-store/immune-checkpoints-activators>

Japan Healthcare Outlook Market- <https://www.delveinsight.com/report-store/japan-healthcare-outlook-report>

Joint Reconstruction Devices Market- <https://www.delveinsight.com/report-store/joint-reconstruction-devices-market>

Mantle Cell Lymphoma Market- <https://www.delveinsight.com/report-store/mantle-cell-lymphoma-market>

Methicillin-resistant Staphylococcus Aureus Infection Market- <https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market>

Mouth Neoplasms Market- <https://www.delveinsight.com/report-store/mouth-neoplasms-market>

Myocardial Infarction Market- <https://www.delveinsight.com/report-store/myocardial-infarction-market>

Neuroendocrine Tumor Market- <https://www.delveinsight.com/report-store/neuroendocrine-tumors-market>

Nocturia Market- <https://www.delveinsight.com/report-store/nocturia-market>

Obstructive Sleep Apnea Market- <https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market>

Phototherapies For Psoriasis Market- <https://www.delveinsight.com/report-store/phototherapy-devices-market>

Plaque Modification Devices Market- <https://www.delveinsight.com/report-store/plaque-modification-devices-market>

Polycystic Ovarian Syndrome Market- <https://www.delveinsight.com/report-store/polycystic-ovarian-syndrome-market>

Primary Mediastinal Large B-cell Lymphoma Market- <https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market>

Rosacea Market - <https://www.delveinsight.com/report-store/rosacea-market>

Sarcopenia Market- <https://www.delveinsight.com/report-store/sarcopenia-market>

Testicular Neoplasm Market- <https://www.delveinsight.com/report-store/testicular-neoplasm-market>

Type 1 Diabetes Market- <https://www.delveinsight.com/report-store/type-1-diabetes-market>

Vascular Access Devices Market- <https://www.delveinsight.com/report-store/vascular-access-device-market>

## About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj

DelveInsight

+91 9650213330

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/785675728>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.